Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,947 | 467 | 2,436 |
| Samples | 1,457 | 292 | 1,142 |
| Peptides | 1,208 | 217 | 1,021 |
Function
ADAMTS20 · ADAM metallopeptidase with thrombospondin type 1 motif 20
The protein encoded by this gene is a member of the ADAMTS family of zinc-dependent proteases. The encoded protein has a signal peptide that is cleaved to release the mature peptide, which is secreted and found in the extracellular matrix. This protein may be involved in tissue remodeling. [provided by RefSeq, Sep 2011].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 1187 amino-acid changes on canonical ENST00000389420 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ADAMTS20 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ADAMTS20 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 9/40 22% | 0/0 0% |
| Melanoma | 29/210 14% | 234/1899 12% |
| Non-Small Cell Lung Carcinoma | 47/304 15% | 107/1390 8% |
| Endometrial Carcinoma | 12/42 29% | 38/612 6% |
| Squamous Cell Lung Carcinoma | 5/57 9% | 57/810 7% |
| Glioblastoma | 7/98 7% | 0/0 0% |
| Neuroendocrine Tumour | 41/154 27% | 6/577 1% |
| Small Cell Lung Carcinoma | 3/9 33% | 36/752 5% |
| Other Solid Cancers | 8/94 9% | 67/1515 4% |
| Acute Myeloid Leukemia | 4/90 4% | 0/0 0% |
| Colorectal Carcinoma | 29/143 20% | 111/3239 3% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Gastric Carcinoma | 6/74 8% | 69/1809 4% |
| Acute Monocytic Leukemia | 0/1 0% | 1/25 4% |
| Biliary Tract Carcinoma | 3/54 6% | 24/950 3% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Hepatocellular Carcinoma | 7/46 15% | 48/2210 2% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 61/2550 2% |
| Bladder Carcinoma | 0/58 0% | 23/956 2% |
| Other Sarcomas | 5/69 7% | 12/699 2% |
| Cervical Carcinoma | 1/35 3% | 9/422 2% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
| Plasma Cell Myeloma | 4/44 9% | 3/305 1% |
| Ovarian Carcinoma | 9/109 8% | 13/998 1% |
| Osteosarcoma | 4/45 9% | 0/166 0% |
| Esophageal Carcinoma | 1/23 4% | 14/769 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Burkitts Lymphoma | 4/32 12% | 0/196 0% |
| Head and Neck Carcinoma | 4/85 5% | 23/1574 1% |
| Non-Cancerous | 2/104 2% | 13/830 2% |
Mutation Distribution
Where ADAMTS20 is mutated · all tissues, split by cell line vs tissue
How many mutations in ADAMTS20 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 12 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,947 mutations in ADAMTS20
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|